



Supplemental Figure 2: Overall response to pembrolizumab monotherapy (n=31, left) and combination therapy (n=34*, right).


Pembrolizumab





Number at risk





Pembro + Chemotherapy




Number at risk



Number at risk



Number at risk



*One patient who received PC was lost to follow-up and unevaluable for OS and PFS.